Edition:
United States

UnitedHealth Group Inc (UNH.N)

UNH.N on New York Stock Exchange

193.43USD
10:56am EDT
Change (% chg)

$1.68 (+0.88%)
Prev Close
$191.75
Open
$192.31
Day's High
$194.32
Day's Low
$192.31
Volume
174,049
Avg. Vol
834,691
52-wk High
$200.76
52-wk Low
$133.03

Latest Key Developments (Source: Significant Developments)

UnitedHealth Group Inc declares quarterly dividend
Wednesday, 10 Feb 2016 06:50am EST 

UnitedHealth Group Inc:Board authorizes payment of quarterly dividend to shareholders.Sets quarterly dividend of $0.50 per share.  Full Article

UnitedHealth Group Inc affirms FY 2016 outlook
Tuesday, 19 Jan 2016 05:55am EST 

UnitedHealth Group Inc:Affirmed its FY 2016 outlook, including estimated revenues of more than $180 billion, rising net earnings growth to a range of $7.60 to $7.80 in adjusted earnings per share.  Full Article

UnitedHealth Group Inc - NY orders UnitedHealth to pay $100,000 to settle antitrust probe - Reuters
Wednesday, 6 Jan 2016 01:30pm EST 

UnitedHealth Group Inc:The New York Attorney General has ordered UnitedHealth Group to pay a $100,000 fine after an investigation found the insurance provider engaged in anti-competitive practices involving elder and long-term care products, according to a person familiar with the matter - RTRS.The settlement, which was signed late Wednesday, centers on efforts by UnitedHealth to force nursing homes to purchase other additional unwanted insurance services in order to participate in the insurance carrier's broader network, the person added - RTRS.The person spoke to Reuters anonymously, because the settlement has not yet been made public. - RTRS.In addition to paying a fine to settle the case, UnitedHealth also agreed to cease its practice of requiring nursing homes to purchase multiple insurance products. - RTRS.The investigation, which had not been previously reported, was sparked by complaints about the company's conduct - RTRS.  Full Article

Photo

Pfizer files suit against J&J over Remicade contracts

Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson , saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.